The role of hypoglycemia in the development of cardiovascular catastrophes (experience of clinical studies)


Cite item

Full Text

Abstract

According to the Clinical recommendations "Algorithms of specialized medical care for patients with diabetes mellitus", and receiving hypoglycemic therapy, it is advisable to start at a plasma glucose level <3.9 mmol/l. According to a prospective study, more than 85% of patients with DM1 recorded at least one confirmed hypoglycemic episode within 30 days. Numerous studies show that with DM1, an average of 0.5 to 5 severe hypoglycemic events are observed annually. The main cause of hypoglycemia is an excess of insulin in the body in relation to the intake of carbohydrates from the outside (with food) or from endogenous sources (production of glucose by the liver), as well as with accelerated utilization of carbohydrates (muscle work). Hypoglycemia causes reaction of the sympathetic nervous system, altered the morphology of the t wave, increased procoagulant state, inflammation, proterochampsa reaction, and endothelial dysfunction. Regular self-monitoring can reduce, and in some cases prevent the development of hypoglycemia.

About the authors

E. V Doskina

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: Evd-evd2008@yandex.ru
канд. мед. наук, доц. каф. эндокринологии 125995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

I. I Almazova

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

канд. мед. наук, ассистент каф. терапии и подростковой медицины 125995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

B. M Tanhilevich

City Clinical Hospital S.P.Botkin of the Department of Health of Moscow

канд. мед. наук, врач анестезиолог-реаниматолог, зав. 61-м отд-нием 125284, Russian Federation, Moscow, 2-y Botkinskiy pr-d, d. 5

References

  1. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. 2017 г.
  2. Cariou B, Fontaine P, Eschwege E. Frequency and predictors of confirmed hypoglycemia in type 1 and insulin-treated type 2 dabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabet Metab 2015; 41 (2): 116-25.
  3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
  4. Reichard P, Berglund B, Britz A. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101-8.
  5. MacLeod K.M, Hepburn D.A, Frier B.M. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238-45.
  6. Khunti K, Alsifri S, Aronson R. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabet Obes Metab 2016; 18 (9): 907-15.
  7. Herman W.H, Ilag L.L, Johnson S.L et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with Type 2 Diabetes. Diabetes Care 2005; 28: 1568-73.
  8. Hurst R.T, Lee R.W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003; 139: 824-34.
  9. Kip K.E, Faxon D.P, Detre K.M et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94: 1818-25.
  10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
  11. Stamler J, Vaccaro O, Neaton J.D et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
  12. Alderman E.L, Corley S.D, Fisher L.D et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141-54.
  13. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995; 75: 894-903.
  14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
  15. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-22.
  16. http: //www.athero.ru/UKPDS-intens-standard.pdf
  17. Акчурин Р.С., Власова Э.Е., Мершин К.В. Сахарный диабет и хирургическое лечение ишемической болезни сердца. Вестн. РАМН. 2012; 1: 14-9. / Akchurin R.S., Vlasova E.E., Mershin K.V. Saharnyj diabet i hirurgicheskoe lechenie ishemicheskoj bolezni serdca. Vestn. RAMN. 2012; 1: 14-9. [in Russian]
  18. Soinio M, Marniemi J, Laakso M et al. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. A 7-year follow-up study. Diabetes Care 2006;29 (2): 329-33.
  19. Nathan David M et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. Diabetes 2013; 62 (12): 3976-86.
  20. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005; 353: 2643-53.
  21. Writing Group for the DCCT/EDIC Research Group. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA 2015; 313 (1): 45-53.
  22. Cleary P.A, Orchard T.J, Genuth S et al. The effect of intensive glycemic treatment on Coronary Artery Calcification on Type 1 Diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55.
  23. Farhmann E.R, Adkins L, Loader J et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complcations trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract 2015; 107 (2): 280-9.
  24. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 1991; 34 (12): 877-90.
  25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53.
  26. Holman R.R, Paul S.K, Bethel M.A et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15): 1577-89.
  27. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545-59.
  28. Bonds D.E, Miller M.E, Bergenstal R.M et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
  29. Riddle M.C. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122 (8): 844-6.
  30. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560-72.
  31. Duckworth W, Abraira C, Moritz T VADT Investigators et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med 2009; 360: 129-39.
  32. Saremi A, Bahn G.D, Reaven P.D. A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) Diabetes Care 2016; pii: dc152107.
  33. Hayward R.A, Reaven P.D, Emanuele N.V. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373 (10): 978.
  34. Gerstein H.C, Bosch J, Dagenais G.R et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367 (4): 319-28.
  35. Mellbin L.G, Rydén L, Riddle M.C et al. ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013; 34 (40): 3137-44.
  36. Bedenis R, Price A.H, Robertson C.M et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. A large clinical trial with some markers of inflammation that may serve as a starting-point for future trials. Diabetes Care 2014; 37 (12): 3301-8.
  37. Gota A, Arah O.A, Goto M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533. doi: 10.1136/bmj.f4533
  38. Gota A, Arah O.A, Goto M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533. doi: 10.1136/bmj.f4533
  39. Глюкометр Контур Плюс. http: //diabetes.ascensia.com.ru/ homepage/ / Gliukometr Kontur Plius. http: //diabetes. ascensia.com.ru/homepage/ [in Russian]
  40. Baum et al. Improving the Quality of Self-Monitoring Blood Glucose Measurement: A Study in Reducing Calibration Errors. Diab Tech Ther 2006; 8 (3): 347-57.

Copyright (c) 2018 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies